News

Public · Published

INOVIQ Signs Agreement with Sonic Healthcare to Advance EXO-OC Ovarian Cancer Detection Test

INOVIQ signed a validation and licence option agreement with Sonic Healthcare USA for its EXO-OC ovarian cancer detection test. Sonic can transfer, optimise and validate the test at a New York state laboratory, with an option to seek a future licence to offer it as a laboratory developed test, subject to successful validation and commercial discussions.

Published:

Updated:

What happened

INOVIQ signed a validation and licence option agreement with Sonic Healthcare USA for its EXO-OC ovarian cancer detection test. Sonic can transfer, optimise and validate the test at a New York state laboratory, with an option to seek a future licence to offer it as a laboratory developed test, subject to successful validation and commercial discussions.

Confirmed

Global impact / market context

Sonic’s laboratory work could give INOVIQ a route toward offering EXO-OC through a US testing service, but the licence is not guaranteed. If validation succeeds and commercial discussions lead to a licence, earlier access to the US diagnostics market could create revenue; otherwise, commercialisation may be delayed.

Analyst inference

The agreement places test optimisation and validation alongside INOVIQ’s planned US clinical-sample collection, regulatory work and reimbursement activities. These steps address whether EXO-OC can be validated and offered as a laboratory developed test, a test run by a laboratory rather than sold as an approved commercial kit.

Confirmed

What to watch

  1. Watch for completion of Sonic’s optimisation and validation work, which tests whether EXO-OC performs well enough to support the proposed laboratory service. Analyst inference
  2. INOVIQ anticipates the optimisation and validation program needed to advance EXO-OC toward laboratory developed test commercialisation will be finalised by early 2028. Confirmed
  3. Track whether INOVIQ’s US clinical-sample collection and regulatory and reimbursement activities progress, since setbacks could delay patient access and any revenue from the test. Analyst inference

Evidence